Infex Therapeutics has presented new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa (Pa). The results were presented at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain. … Read More
Infex Therapeutics, in collaboration with Justus-Liebig-University Giessen (JLU), Germany, has been awarded a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy). The company plans to develop a first-in-class BamA inhibitor targeting multi-drug-resistant (MDR) Gram-negative pathogens. BamA inhibitors are an entirely new class of antimicrobial drug designed to target… Read More
In preclinical studies, a new pan-coronavirus papain-like protease (PLpro) inhibitor has shown a near complete reduction in SARS-CoV-2 viral load in the lungs. Infex Therapeutics has selected the clinical candidate for its in-house COV-X programme based on this in vivoefficacy data in a murine SARS-CoV-2 model. Read More
RESP-X, Infex Therapeutics’ anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients, has shown a promising interim safety and tolerability profile in its ongoing first-in-human Phase I clinical trial. The first cohort consisted of eight healthy volunteers who received doses of… Read More
